These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27855072)

  • 21. Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.
    Pradelli J; Risso K; de Salvador FG; Cua E; Ruimy R; Roger PM
    Eur J Clin Microbiol Infect Dis; 2015 Mar; 34(3):511-8. PubMed ID: 25273975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
    Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
    Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus β-lactams.
    Mercuro NJ; Stogsdill P; Wungwattana M
    Int J Antimicrob Agents; 2018 May; 51(5):687-692. PubMed ID: 29284155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity.
    To KK; Lo WU; Chan JF; Tse H; Cheng VC; Ho PL
    Int J Infect Dis; 2013 Feb; 17(2):e120-4. PubMed ID: 23098812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factor of community-onset spontaneous bacterial peritonitis caused by fluoroquinolone-resistant Escherichia coli in patients with cirrhosis.
    Kim J; Kang CI; Joo EJ; Ha YE; Cho SY; Gwak GY; Chung DR; Peck KR; Song JH
    Liver Int; 2014 May; 34(5):695-9. PubMed ID: 24267669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of fluoroquinolone use in the respiratory intensive care unit on the development of hospital-acquired MRSA infection and its prognosis].
    Dirican N; Oz AT; Pullukçu H; Aydemir S; Bacakoğlu F
    Mikrobiyol Bul; 2014 Jan; 48(1):28-39. PubMed ID: 24506713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.
    Lee JY; Lee HJ; Kim YK; Yu S; Jung J; Chong YP; Lee SO; Choi SH; Shim TS; Kim YS; Woo JH; Kim SH
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4005-12. PubMed ID: 27090178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved survival in patients with severe tuberculosis after exposure to fluoroquinolones.
    Chiang SR; Shieh JM; Chen CH; Hsing SC; Wen SF; Wang JJ; Cheng KC; Chuang YC
    Infect Dis (Lond); 2016; 48(11-12):789-95. PubMed ID: 27329552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of broad-spectrum antibiotics in French EDs: different trends for third-generation cephalosporins and fluoroquinolones.
    Batard E; Vibet MA; Lemarchand C; Navas D; Lepelletier D; Potel G; Montassier E;
    Eur J Emerg Med; 2017 Jun; 24(3):189-195. PubMed ID: 26426738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; de Cueto M; Ríos MJ; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Dec; 43(11):1407-14. PubMed ID: 17083012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
    Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study.
    Lee CC; Hsieh CC; Yang CY; Hong MY; Lee CH; Tang HJ; Ko WC
    Int J Antimicrob Agents; 2019 Aug; 54(2):176-183. PubMed ID: 31108223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolone versus Beta-Lactam Oral Step-Down Therapy for Uncomplicated Streptococcal Bloodstream Infections.
    Arensman K; Shields M; Beganovic M; Miller JL; LaChance E; Anderson M; Dela-Pena J
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etiologies of community-onset urinary tract infections requiring hospitalization and antimicrobial susceptibilities of causative microorganisms.
    Chiu CC; Lin TC; Wu RX; Yang YS; Hsiao PJ; Lee Y; Lin JC; Chang FY
    J Microbiol Immunol Infect; 2017 Dec; 50(6):879-885. PubMed ID: 28087318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of hospitalized neutropenic oncology patients with Pseudomonas aeruginosa bloodstream infections: focus on oral fluoroquinolone conversion.
    Yan LZ; Herrington JD
    J Oncol Pharm Pract; 2016 Aug; 22(4):584-90. PubMed ID: 26156260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Second- and Third-Generation Cephalosporin as Initial Therapy for Women with Community-Onset Uncomplicated Acute Pyelonephritis.
    Chang UI; Kim HW; Wie SH
    Yonsei Med J; 2015 Sep; 56(5):1266-73. PubMed ID: 26256969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propensity-matched analysis to compare the therapeutic efficacies of cefuroxime versus cefotaxime as initial antimicrobial therapy for community-onset complicated nonobstructive acute pyelonephritis due to Enterobacteriaceae infection in women.
    Chang UI; Kim HW; Wie SH
    Antimicrob Agents Chemother; 2015 May; 59(5):2488-95. PubMed ID: 25645837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of Gram-negative nonfermenters on adults with community-onset bacteremia in the emergency department.
    Chiu CW; Li MC; Ko WC; Li CW; Chen PL; Chang CM; Lee NY; Lee CC
    J Microbiol Immunol Infect; 2015 Feb; 48(1):92-100. PubMed ID: 24060496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.